4 trials - ESTABLISH - PROVE IT - TIMI 22 - Colivicchi - MIRACL
Patient with history of atrial fibrillation: 5 trials - Almroth - Dernellis - Ozaydin - MIRACL (sub-group) (Schwartz) - STOP-AF
Patients without history of AF (primary prevention): 3 trials - ARMYDA-3 (AF ancillary study) - Chello - MIRACL (AF ancillary study)
2 trials - Chello et al. - Patti et al.
All chronical situations: 15 trials - SAGE - ASPEN - SPARCL - Deutsche Diabetes Dialyse Studie (4D) - IDEAL - Strey - TNT - Vascular basis - CARDS - PROVE-IT - REVERSAL - ASCOT - Mohler III - GREACE - AVERT
Diabetic patients : 6 trials - ASPEN - ASPEN - TNT (diabetic sub group) - Deutsche Diabetes Dialyse Studie (4D) - CARDS - ASCOT (diabetics sub group)
High risk patients with or without LDL cholesterol elevation: 1 trials - ASCOT
Hypertensive patients: 1 trials - ASCOT
Patient with related disease: 1 trials - SALTIRE
Patients with prior MI or with CHD: 12 trials - SAGE - IDEAL - macin - TNT - Vascular basis - ESTABLISH - PROVE IT - TIMI 22 - PROVE-IT - REVERSAL - Colivicchi - GREACE - MIRACL
Patients with renal insufficiency (on hemodialysis or transplant): 1 trials - Deutsche Diabetes Dialyse Studie (4D)
Post stroke (or TIA) : 1 trials - SPARCL
Primary prevention: 4 trials - ASPEN (primary prevention sub group) - CARDS - ASCOT - Mohler
Secondary prevention: 8 trials - SAGE - IDEAL - TNT - Vascular basis - REVERSAL - Mohler - GREACE - AVERT
Women: 1 trials - ASCOT (women subgroup)
Diabetic patients with or withour hypercholesterolemia: 4 trials - ASPEN - TNT (diabetic sub group) - CARDS - ASCOT (diabetics sub group)
Primary prevention: 3 trials - ASPEN (primary prevention sub group) - CARDS - ASCOT (diabetics sub group)
Secondary prevention: 1 trials - TNT (diabetic sub group)
All type of patients: 4 trials - Yamada - Sola - Wojnicz - Strey
5 trials - ARMYDA-RECAPTURE - NAPLES II (Briguori) - ARMYDA - GAIN - ESTATE
5 trials - SAGE - IDEAL - TNT - Vascular basis - REVERSAL